Renal impairment (RI) is a relevant complication of patients affected by multiple myeloma (MM); it can be present in up to 30–35% of newly diagnosed MM and is linked to a poor outcome. However, early recognition and early treatment with novel agents can overcome the negative impact of RI and even reverse kidney damage in most cases. Lenalidomide, available as an oral compound, is an immunomodulatory drug with both antiproliferative and immunomodulatory activity that is largely used in the management of MM. Dose reduction is mandatory in RI; however, there is no theoretical assumption against the possibility that protracting the time of full standard doses can be equally effective and tolerated by patients requiring reduced doses. In this report, we describe our retrospective experience, in 18 patients, with the administration of lenalidomide 25 mg every other day for patients with MM and RI. The overall response ratio was 66.5%. More than half (61.1%) of the patients had a renal response. The median progression-free survival was 8 months (range: 3–18 months). No serious adverse event occurred during treatment, and it was never necessary to disrupt or delay treatment for toxicity. These preliminary observations point to a significant therapeutic effect of lenalidomide, at the dose of 25 mg every other day for 21 days, with logistic and economic advantages. However, these results should be validated by controlled studies involving larger numbers of patients.
Departments of aClinical Medicine, Division of Hematology
bAdvanced Biomedical Science, University Federico II, Naples
cAge Related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy
Correspondence to Claudio Cerchione, MD, PhD, Department of Clinical Medicine, Division of Hematology, University Federico II, Via Pansini 5, 80131 Naples, Italy Tel: +39 01 746 2037; fax: +39 081 746 2165; e-mail: email@example.com
Received July 24, 2017
Accepted January 18, 2018